The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Open accessAbstract
BACKGROUND: Intratumor heterogeneity may foster tumor evolution and adaptation and hinder personalized-medicine strategies that depend on results from single tumor-biopsy samples. METHODS: To examine intratumor heterogeneity, we performed exome sequencing, chromosome aberration analysis, and ploidy profiling on multiple spatially separated samples obtained from primary renal carcinomas and associated metastatic sites. We characterized the consequences of intratumor heterogeneity using immunohistochemical analysis, mutation functional analysis, and profiling of messenger RNA expression. RESULTS: Phylogenetic reconstruction revealed branched evolutionary tumor growth, with 63 to 69% of all somatic mutations not detectable across every tumor region. Intratumor heterogeneity was observed for a mutation within an autoinhibitory domain of the mammalian target of rapamycin (mTOR) kinase, correlating with S6 and 4EBP phosphorylation in vivo and constitutive activation of mTOR kinase activity in vitro. Mutational intratumor heterogeneity was seen for multiple tumor-suppressor genes converging on loss of function; SETD2, PTEN, and KDM5C underwent multiple distinct and spatially separated inactivating mutations within a single tumor, suggesting convergent phenotypic evolution. Gene-expression signatures of good and poor prognosis were detected in different regions of the same tumor. Allelic composition and ploidy profiling analysis revealed extensive intratumor heterogeneity, with 26 of 30 tumor samples from four tumors harboring divergent allelic-imbalance profiles and with ploidy heterogeneity in two of four tumors. CONCLUSIONS: Intratumor heterogeneity can lead to underestimation of the tumor genomics landscape portrayed from single tumor-biopsy samples and may present major challenges to personalized-medicine and biomarker development. Intratumor heterogeneity, associated with heterogeneous protein function, may foster tumor adaptation and therapeutic failure through Darwinian selection. (Funded by the Medical Research Council and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A greater degree of divergence may be attributed to intra-tumor spatial heterogeneity and sampling bias: tumors can be spatially diverse, and organoids generated from a specific portion may lack the representativeness of distant regions130,131.”
From Organoids (2022) · cites this paper as [130]
Experimental — accuracy not yet measuredIn the citing paper
“a small needle biopsy of a single lesion may fail to reflect the true underlying intra- and inter-tumor genetic heterogeneity (15–17).”
In the citing paper
“It is now appreciated that most clinically relevant solid tumors are highly heterogeneous at the phenotypic, physiologic, and genomic levels (13–15) and that they continue to evolve over time.”
From Radiomics: Images Are More than Pictures, They Are Data (2016) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161
Tumour evolution inferred by single-cell sequencing
Navin, N., Kendall, J., Troge, J., Andrews, P., Rodgers, L., McIndoo, J., Cook, K., Stepansky, A., Levy, D., Esposito, D., et al. (2011) · Nature · doi:10.1038/nature09807 · Cited by 2,598
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R. H., Eshleman, J. R., Nowak, M. A., et al. (2010) · Nature · doi:10.1038/nature09515 · Cited by 2,502
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Cancer as an evolutionary and ecological process
Merlo, L. M. F., Pepper, J. W., Reid, B. J., & Maley, C. C. (2006) · Nature reviews. Cancer · doi:10.1038/nrc2013 · Cited by 1,743
Flanigan, R. C., Salmon, S. E., Blumenstein, B. A., Bearman, S. I., Roy, V., McGrath, P. C., Caton, J. R., Munshi, N. C., & Crawford, E. D. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa003013 · Cited by 1,710
Detection of Mutations in EGFR in Circulating Lung-Cancer Cells
Maheswaran, S., Sequist, L. V., Nagrath, S., Ulkus, L., Brannigan, B., Collura, C. V., Inserra, E., Diederichs, S., Iafrate, A. J., Bell, D. W., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800668 · Cited by 1,617
Flagged first, then by citations
Cited by
Sorted by citations
Items 701–800 of 1,049
Challenges and Promises of PET Radiomics
Cook, G., Azad, G. K., Owczarczyk, K. M., Siddique, M. M., & Goh, V. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.12.268 · Cited by 167
“Genotypic heterogeneity contributes to the development of subpopulations of cells with divergent biological behavior that are resistant to treatment (5).”
BackgroundMicrofluidic technologies for circulating tumor cell isolation
Cho, H., Kim, J., Song, H., Sohn, K. Y., Jeon, M., & Han, K.-H. (2018) · The Analyst · doi:10.1039/c7an01979c · Cited by 167
Pestrin, M., Salvianti, F., Galardi, F., Luca, F. D., Turner, N. H., Malorni, L., Pazzagli, M., Leo, A. D., & Pinzani, P. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.12.001 · Cited by 168
Tackling the Diversity of Triple-Negative Breast Cancer
Turner, N. C., & Reis-Filho, J. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0915 · Cited by 175
VHL Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma
Yao, X., Tan, J. Y., Lim, K. J., Koh, J., Ooi, W. F., Li, Z., Huang, D., Xing, M., Chan, Y. S., Qu, J. Z., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0375 · Cited by 171
Cancer biomarkers: Written in blood
Yong, E. (2014) · Nature · doi:10.1038/511524a · Cited by 167
Liposome imaging agents in personalized medicine
Petersen, A. L., Hansen, A. E., Gabizon, A., & Andresen, T. L. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.003 · Cited by 164
Guttery, D. S., Page, K., Hills, A., Woodley, L., Marchese, S. D., Rghebi, B., Hastings, R. K., Luo, J., Pringle, J. H., Stebbing, J., et al. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2015.238717 · Cited by 170
Clonal evolution in hematological malignancies and therapeutic implications
Landau, D. A., Carter, S. L., Getz, G. A., & Wu, C. J. (2013) · Leukemia · doi:10.1038/leu.2013.248 · Cited by 173
Prioritizing targets for precision cancer medicine
André, F., Mardis, E. R., Salm, M. P., Soria, J., Siu, L. L., & Swanton, C. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu478 · Cited by 169
Self-citationDavis, R. J., Waes, C. V., & Allen, C. T. (2016) · Oral Oncology · doi:10.1016/j.oraloncology.2016.05.002 · Cited by 167
“Many different cell types and functional states contribute to the overall immunosuppressive or immunopermissive status of the TME, and this can vary between patients and even regionally within one tumor [17].”
BackgroundMicrofluidic: An innovative tool for efficient cell sorting
Autebert, J., Coudert, B., Bidard, F., Pierga, J., Descroix, S., Malaquin, L., & Viovy, J. (2012) · Methods · doi:10.1016/j.ymeth.2012.07.002 · Cited by 173
Measuring cancer evolution from the genome
Graham, T. A., & Sottoriva, A. (2016) · The Journal of Pathology · doi:10.1002/path.4821 · Cited by 182
“These methods have been applied to a wide variety of cancers and revealed new insight into the order and timing of mutation accumulation (for some examples see refs [9-25]).”
MethodCombating subclonal evolution of resistant cancer phenotypes
Brady, S. W., McQuerry, J. A., Qiao, Y., Piccolo, S., Shrestha, G., Jenkins, D. F., Layer, R. M., Pedersen, B. S., Miller, R. H., Esch, A. M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01174-3 · Cited by 163
“Samples were obtained before, during, or after the following treatments: (1) capecitabine, (2) exemestane, (3) exemestane and everolimus, (4) vinorelbine, (5) carboplatin and gemcitabine, (6) fulvestrant, (7) liposomal doxorubicin, (8) paclitaxel, (9) Abraxane, and (10) eribulin (Fig.”
InfluentialEvolutionary medicine: its scope, interest and potential
Stearns, S. C. (2012) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.2012.1326 · Cited by 163
State of the Science: An Update on Renal Cell Carcinoma
Jonasch, E. W., Futreal, P. A., Davis, I. J., Bailey, S. T., Kim, W. Y., Brugarolas, J., Giaccia, A. J., Kurban, G., Pause, A., Frydman, J., et al. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0117 · Cited by 165
Self-citationRevisiting tumour aneuploidy — the place of ploidy assessment in the molecular era
Danielsen, H. E., Pradhan, M., & Novelli, M. R. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.208 · Cited by 161
SETD2: an epigenetic modifier with tumor suppressor functionality
Li, J., Duns, G., Westers, H., Sijmons, R. H., van den Berg, A., & Kok, K. (2016) · Oncotarget · doi:10.18632/oncotarget.9368 · Cited by 163
“Gerlinger et al [109] carried out a genomic analysis of multiple regions of four primary ccRCC tumors and detected intratumor heterogeneity in every case.”
BackgroundPancreatic Cancer Genomes: Implications for Clinical Management and Therapeutic Development
Dreyer, S. B., Chang, D. K.-F., Bailey, P. J., & Biankin, A. V. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2411 · Cited by 168
Exosomes as a liquid biopsy for lung cancer
Cui, S., Cheng, Z., Qin, W., & Jiang, L. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.12.012 · Cited by 167
Genetic and metabolic hallmarks of clear cell renal cell carcinoma
Sanchez, D. J., & Simon, M. C. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.06.003 · Cited by 164
“For example, gene expression patterns associated with both good and poor prognoses can be found within the same tumor, and roughly 2/3rd of all somatic mutations are not detectable in every sequenced region [23].”
BackgroundA review of original articles published in the emerging field of radiomics
Song, J., Yin, Y., Wang, H., Chang, Z., Liu, Z., & Cui, L. (2020) · European Journal of Radiology · doi:10.1016/j.ejrad.2020.108991 · Cited by 163
Cancer Stem Cells—Key Players in Tumor Relapse
Marzagalli, M., Fontana, F., Raimondi, M., & Limonta, P. (2021) · Cancers · doi:10.3390/cancers13030376 · Cited by 177
A narrative review of tumor heterogeneity and challenges to tumor drug therapy
Zhu, L. W., Jiang, M., Wang, H., Sun, H., Zhu, J., Zhao, W., Fang, Q., Yu, J., Chen, P., Wu, S., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-1948 · Cited by 179
“(24) found that only 34% of the mutations identified were consistent in all samples when several sites and metastases were detected in patients with the same primary renal tumor.”
BackgroundJoseph, R. W., Kapur, P., Serie, D., Eckel‐Passow, J. E., Parasramka, M. A., Ho, T. H., Cheville, J. C., Frenkel, E. P., Rakheja, D., Brugarolas, J., et al. (2013) · Cancer · doi:10.1002/cncr.28521 · Cited by 165
Kim, T., Jung, S., An, C. H., Lee, S. H., Baek, I.-P., Kim, M. S., Park, S., Rhee, J., Lee, S.-H., & Chung, Y. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2413 · Cited by 161
Dunne, P. D., McArt, D. G., Bradley, C. A., O’Reilly, P. G., Barrett, H. L., Cummins, R., O’Grady, T., Arthur, K., Loughrey, M. B., Allen, W. L., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0032 · Cited by 162
“Multiregion sequencing and mutational analysis has highlighted diversity in renal (22) and recently in colorectal cancer (23) patient samples, but our data show that patient classification in colorectal cancer utilizing transcriptional profiling is associated as much with the region from where the sample is derived fr…”
BackgroundYip, S. S. F., Kim, J., Coroller, T. P., Parmar, C., Velazquez, E. R., Huynh, E., Mak, R. H., & Aerts, H. J. W. L. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.181826 · Cited by 164
“procedures, long processing times, sampling error, and tissue samples are not always readily available (9-11).”
BackgroundFrequently mutated genes/pathways and genomic instability as prevention targets in liver cancer
Rao, C. V., Asch, A. S., & Yamada, H. Y. (2016) · Carcinogenesis · doi:10.1093/carcin/bgw118 · Cited by 163
Epigenetics in renal cell cancer: mechanisms and clinical applications
Joosten, S. C., Smits, K. M., Aarts, M. J. B., Melotte, V., Koch, A., Tjan‐Heijnen, V. C. G., & van Engeland, M. (2018) · Nature Reviews Urology · doi:10.1038/s41585-018-0023-z · Cited by 166
Sharma, A., Cao, E. Y., Kumar, V., Zhang, X., Leong, H. S., Wong, A. M. L., Ramakrishnan, N., Hakimullah, M., Teo, H. M. V., Chong, F. T., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07261-3 · Cited by 159
Cheng, Q., Butler, W., Zhou, Y., Zhang, H., Tang, L., Perkinson, K., Chen, X., Jiang, X. “., McCall, S. J., Inman, B. A., et al. (2022) · European Urology · doi:10.1016/j.eururo.2021.12.039 · Cited by 165
“The genomic landscape of tumors can be elucidated from single tumor biopsy samples, when a large number of tumor cells are analyzed [39,40].”
BackgroundAcquired resistance to EGFR‐targeted therapies in colorectal cancer
Emburgh, B. O. V., Bianchi, A. S., Nicolantonio, F. D., Siena, S., & Bardelli, A. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.05.003 · Cited by 162
Single-cell genotyping demonstrates complex clonal diversity in acute myeloid leukemia
Paguirigan, A. L., Smith, J. L., Meshinchi, S., Carroll, M. P., Maley, C. C., & Radich, J. P. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa0763 · Cited by 159
Metastasis in renal cell carcinoma: Biology and implications for therapy
Gong, J., Maia, M. C., Dizman, N., Govindarajan, A., & Pal, S. K. (2016) · Asian journal of urology · doi:10.1016/j.ajur.2016.08.006 · Cited by 161
“One of the first detailed studies to identify this intratumoral heterogeneity was from Gerlinger and colleagues [24].”
BackgroundGrassi, L., Alfonsi, R., Francescangeli, F., Signore, M., Angelis, M. L. D., Addario, A., Costantini, M., Flex, E., Ciolfi, A., Pizzi, S., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1453-0 · Cited by 167
Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer
Siravegna, G., Lazzari, L., Crisafulli, G., Bianchi, A. S., Mussolin, B., Cassingena, A., Martino, C., Lanman, R. B., Nagy, R. J., Fairclough, S. R., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.06.004 · Cited by 159
A glimpse into past, present, and future DNA sequencing
Morey, M., Marmiesse, A. F., Castiñeiras, D. E., Fraga, J. M., Couce, M. L., & Cocho, J. A. (2013) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2013.04.024 · Cited by 177
Seipin: from human disease to molecular mechanism
Cartwright, B. R., & Goodman, J. M. (2012) · Journal of Lipid Research · doi:10.1194/jlr.r023754 · Cited by 160
Jilaveanu, L. B., Shuch, B. M., Zito, C. R., Parisi, F., Barr, M. L., Kluger, Y., Chen, L., & Kluger, H. M. (2014) · Journal of Cancer · doi:10.7150/jca.8167 · Cited by 156
Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality?
Ignatiadis, M., & Dawson, S. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu480 · Cited by 161
Ursprung, S., Beer, L., Bruining, A., Woitek, R., Stewart, G. D., Gallagher, F. A., & Sala, E. (2020) · European Radiology · doi:10.1007/s00330-020-06666-3 · Cited by 168
Tracking Cancer Evolution through the Disease Course
Bailey, C., Black, J. R., Reading, J. L., Litchfield, K., Turajlic, S., McGranahan, N., Jamal‐Hanjani, M., & Swanton, C. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1559 · Cited by 159
“Significant intratumor heterogeneity of mutations and somatic copy-number alterations (SCNA) had also been described (8, 9); TRACERx Renal aimed to explore associations between this intratumor heterogeneity and the diversity of clinical outcomes.”
Self-citationMcDermott, D. F., Cheng, S., Signoretti, S., Margolin, K. A., Clark, J. I., Sosman, J. A., Dutcher, J. P., Logan, T. F., Curti, B. D., Ernstoff, M. S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1520 · Cited by 157
Keysar, S. B., Astling, D. P., Anderson, R. T., Vogler, B. W., Bowles, D. W., Morton, J. J., Paylor, J. J., Glogowska, M. J., Le, P. N., Eagles-Soukup, J. R., et al. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.03.004 · Cited by 160
Smedt, L. D., Lemahieu, J., Palmans, S., Govaere, O., Tousseyn, T., Cutsem, E. V., Prenen, H., Tejpar, S., Spaepen, M., Matthijs, G., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.213 · Cited by 161
“Therefore, all tumour components should be investigated individually to overcome inaccuracies due to the heterogeneous nature of the tumour (Gerlinger et al, 2012; Bedard et al, 2013; Burrell et al, 2013).”
BackgroundDiagnostic performance of texture analysis on MRI in grading cerebral gliomas
Skogen, K., Schulz, A., Dormagen, J. B., et al. (2016) · European Journal of Radiology · doi:10.1016/j.ejrad.2016.01.013 · Cited by 157
Lee, J. Y., Qing, X., Wei, X., Yali, B., Chi, S., Bak, S. H., Lee, H. Y., Sun, J., Lee, S., Ahn, J. S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.6874 · Cited by 159
“The development of acquired resistance to anticancer therapy derives from clonal evolution and selection [21, 22].”
BackgroundKopka, K., Benešová, M., Bařinka, C., Haberkorn, U., & Babich, J. W. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.186775 · Cited by 161
“Furthermore, gene expression signatures for a good prognosis and a poor prognosis were detected in different regions of the same tumor (88).”
BackgroundPatient‐derived xenografts for individualized care in advanced sarcoma
Stebbing, J., Paz, K., Schwartz, G. K., Wexler, L. H., Maki, R. G., Pollock, R. E., Morris, R., Cohen, R., Shankar, A., Blackman, G., et al. (2014) · Cancer · doi:10.1002/cncr.28696 · Cited by 157
Yang, D., Rao, G., Martinez, J. J., Veeraraghavan, A., & Rao, A. U. K. (2015) · Medical Physics · doi:10.1118/1.4934373 · Cited by 160
Soussan, M., Orlhac, F., Boubaya, M., Zelek, L. H., Ziol, M., Eder, V., & Buvat, I. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094017 · Cited by 156
Designing Transformative Clinical Trials in the Cancer Genome Era
Sleijfer, S., Bogaerts, J., & Siu, L. L. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.3639 · Cited by 156
Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls
Horak, P., Fröhling, S., & Glimm, H. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000094 · Cited by 162
“Nevertheless, the underlying genetic background and the selective pressure of patients’ individual medical histories and treatments invariably lead to much wider heterogeneity than we are able to assess with our current methods, and might be the main cause of treatment failure due to evolutionary adaptation.(106) 107…”
BackgroundGenomic landscape of adenoid cystic carcinoma of the breast
Martelotto, L. G., Filippo, M. R. D., Ng, C. K. Y., Natrajan, R., Fuhrmann, L., Cyrta, J., Piscuoglio, S., Wen, H., Lim, R. S., Shen, R., et al. (2015) · The Journal of Pathology · doi:10.1002/path.4573 · Cited by 157
“Despite the low level of genetic instability observed in breast AdCCs, our results provide evidence to suggest that, in a way akin to other forms of cancer [18,49,50], at diagnosis AdCCs may be constituted by a mosaic of cancer cell clones, with some potentially non-passenger mutations affecting known cancer genes bei…”
ResultAccessing Genetic Information with Liquid Biopsies
Cai, X., Jankú, F., Zhan, Q., & Fan, J. (2015) · Trends in Genetics · doi:10.1016/j.tig.2015.06.001 · Cited by 157
Zhao, L., Lu, Y.-T., Li, F., Wu, K., Hou, S., Yu, J.-H., Shen, Q.-L., Wu, D., Song, M., Ouyang, W., et al. (2013) · Advances in Materials · doi:10.1002/adma.201205237 · Cited by 154
Heralding a new paradigm in 3D tumor modeling
Fong, E. L. S., Harrington, D. A., Farach‐Carson, M. C., & Yu, H. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.08.052 · Cited by 156
SiFit: inferring tumor trees from single-cell sequencing data under finite-sites models
Zafar, H., Tzen, A., Navin, N. E., Chen, K., & Nakhleh, L. K. (2017) · Genome biology · doi:10.1186/s13059-017-1311-2 · Cited by 156
“Another approach for resolving intra-tumor heterogeneity and reconstructing tumor phylogeny is multi-region sequencing, in which DNA sampled from multiple spatially separated regions of the tumor are sequenced [19, 20].”
BackgroundTjensvoll, K., Lapin, M., Buhl, T., Oltedal, S., Berry, K. S.-O., Gilje, B., Søreide, J. A., Javle, M. M., Nordgård, O., & Smaaland, R. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.11.012 · Cited by 157
Decision support systems for personalized and participative radiation oncology
Lambin, P., Zindler, J. D., Vanneste, B. G. L., Voorde, L. V. D., Eekers, D. B. P., Compter, I., Panth, K. M., Peerlings, J., Larue, R. T. H. M., Deist, T. M., et al. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.01.006 · Cited by 162
“genetic [6], epigenetic [7], transcriptomic [8], histological [9] andmicroenvironmental [10] heterogeneity exists within individual tumors,”
BackgroundIntratumor Heterogeneity in Breast Cancer
de Beça, F. F., & Polyák, K. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-22909-6_7 · Cited by 160
Tu, W., Sun, G., Fan, L., Wang, Y., Xia, Y., Guan, Y., Li, Q., Zhang, D., Liu, S., & Li, Z. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.03.025 · Cited by 149
Modeling clear cell renal cell carcinoma and therapeutic implications
Wolf, M. M., Rathmell, W. K., & Beckermann, K. E. (2020) · Oncogene · doi:10.1038/s41388-020-1234-3 · Cited by 170
Towards more effective advanced drug delivery systems1
Crommelin, D. J. A., & Florence, A. T. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.02.020 · Cited by 158
Griffioen, A. W., Mans, L. A., de Graaf, A. M. A., Nowak-Sliwinska, P. M., de Hoog, C. L. M. M., de Jong, T. A. M., Vyth‐Dreese, F. A., B, J. R. V. B., Bex, A., & Jonasch, E. W. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0002 · Cited by 155
Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC)
Wein, L., & Loi, S. (2017) · The Breast · doi:10.1016/j.breast.2017.06.023 · Cited by 153
Ricordel, C., Friboulet, L., Facchinetti, F., & Soria, J. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx705 · Cited by 156
Targeting Cancer Stem Cells to Overcome Chemoresistance
Nunes, T., Hamdan, D., Lebœuf, C., Bouchtaoui, M. E., Gapihan, G., Nguyen, T. T. N., Meles, S., Angeli, E., Ratajczak, P., Lu, H., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19124036 · Cited by 158
“Metastatic renal cancer samples offer the opportunity to study cancer heterogeneity and the role of cancer stem cells in resistance to treatments [1,2,6,58].”
BackgroundEnzyme-Instructed Self-Assembly: A Multistep Process for Potential Cancer Therapy
Zhou, J., & Xu, B. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00196 · Cited by 156
Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients
Schwaederle, M. C., Husain, H., Fanta, P. T., Piccioni, D. E., Kesari, S., Schwab, R. B., Patel, S. P., Harismendy, O., Ikeda, M., Parker, B. A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0318 · Cited by 154
Schmiegel, W., Scott, R. J., Dooley, S., Lewis, W., Meldrum, C. J., Pockney, P. G., Draganic, B. D., Smith, S., Hewitt, C., Phillimore, H., et al. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12023 · Cited by 152
“Studies evaluating the genomic profiles of primary tumors and metastases have shown discordant results, attributed largely to molecular inter- and intratumor/ metastasis heterogeneity (De Mattos-Arruda et al., 2014; Gerlinger et al., 2012; Mao et al., 2015).”
BackgroundRadiographic prediction of meningioma grade by semantic and radiomic features
Coroller, T. P., Bi, W. L., Huynh, E., Abedalthagafi, M., Aizer, A. A., Greenwald, N. F., Parmar, C., Narayan, V., Wu, W. W., de Moura, S. M., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187908 · Cited by 152
“Tumor radiographic heterogeneity has been extensively studied in glioblastoma, lung cancer, renal cell cancer, and other systemic malignancies and is felt to contribute significantly to treatment resistance and disease relapse[48].”
BackgroundAdvances in understanding tumour evolution through single-cell sequencing
Kuipers, J., Jahn, K., & Beerenwinkel, N. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.02.001 · Cited by 148
Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer
Liu, D., Abbosh, P. H., Keliher, D., Reardon, B. M., Miao, D., Mouw, K. W., Taylor-Weiner, A. N., Wankowicz, S. A. M., Han, G. C., Teo, M. Y., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02320-7 · Cited by 149
High-throughput single-сell sequencing in cancer research
Jia, Q., Chu, H., Jin, Z., Long, H., & Zhu, B. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00990-4 · Cited by 157
Epithelial-to-Mesenchymal Transition Rewires the Molecular Path to PI3K-Dependent Proliferation
Salt, M. B., Bandyopadhyay, S., & McCormick, F. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0520 · Cited by 124
Gao, W., Li, W., Xiao, T., Liu, X. S., & Kaelin, W. G. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1619726114 · Cited by 156
“Mass spectrometry analysis confirmed the recovery of BAF180 itself, as well as other members of the canonical PBAF complex, including BAF170, BAF155, BAF200, BAF57, BAF60a, BAF45a, BAF60b, BAF53a, and BAF47 and the SWI/SNF-associated proteins BCL7A and BCL7C.”
ResultKowalik, A., Kowalewska, M., & Góźdź, S. S. (2017) · Translational research · doi:10.1016/j.trsl.2017.04.002 · Cited by 156
The Cancer Cell Map Initiative: Defining the Hallmark Networks of Cancer
Krogan, N. J., Lippman, S. M., Agard, D. A., Ashworth, A., & Ideker, T. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.05.008 · Cited by 154
“In cancer and other complex diseases, the power to detect important germline variants or somatic mutations has been hampered by the extreme genetic heterogeneity observed across the patient population (Gerlinger et al., 2012; Lawrence et al., 2013; Longo, 2012; Zhang et al., 2014).”
BackgroundUsing high-density DNA methylation arrays to profile copy number alterations
Feber, A., Guilhamon, P., Lechner, M., Fenton, T. R., Wilson, G. A., Thirlwell, C., Morris, T. J., Flanagan, A. M., Teschendorff, A. E., Kelly, J. D., et al. (2014) · Genome biology · doi:10.1186/gb-2014-15-2-r30 · Cited by 150
Schwaederle, M. C., Husain, H., Fanta, P. T., Piccioni, D. E., Kesari, S., Schwab, R. B., Banks, K. C., Lanman, R. B., Talasaz, A. H., Parker, B. A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7110 · Cited by 151
“Finally, it is now known that there is molecular heterogeneity within and between tumors in the same patient [14].”
Fibrosis imaging: Current concepts and future directions
Baues, M., Dasgupta, A., Ehling, J., Prakash, J., Boor, P., Tacke, F., Kiessling, F. M., & Lammers, T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.10.013 · Cited by 155
“In tumors, biopsy-based diagnosis is particularly complicated, because of intrinsic heterogeneity in the primary tumor, as well as heterogeneity between the primary tumor and metastases [41].”
BackgroundGenomic and epigenomic heterogeneity in chronic lymphocytic leukemia
Guièze, R., & Wu, C. J. (2015) · Blood · doi:10.1182/blood-2015-02-585042 · Cited by 151
Clinical and molecular complexity of breast cancer metastases
Kimbung, S., Loman, N., & Hedenfalk, I. A. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.08.009 · Cited by 154
Cheng, F., Zhao, J., & Zhao, Z. (2015) · Briefings in Bioinformatics · doi:10.1093/bib/bbv068 · Cited by 151
Evolution of DNA Methylation Is Linked to Genetic Aberrations in Chronic Lymphocytic Leukemia
Oakes, C. C., Claus, R., Gu, L., Assenov, Y., Hüllein, J., Zucknick, M., Bieg, M., Brocks, D., Bogatyrova, O., Schmidt, C. R., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0349 · Cited by 153
Dago, A. E., Stepansky, A., Carlsson, A., Luttgen, M. S., Kendall, J., Baslan, T., Kolatkar, A. R., Wigler, M. H., Bethel, K. J., Gross, M. E., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101777 · Cited by 153
Acidosis and cancer: from mechanism to neutralization
Ibrahim‐Hashim, A., & Estrella, V. C. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09787-4 · Cited by 150
Kwon, M.-C., & Berns, A. J. M. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.02.010 · Cited by 150
Overcoming implementation challenges of personalized cancer therapy
Meric‐Bernstam, F., & Mills, G. B. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.127 · Cited by 150
Integrated Next-Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment
Garralda, E., Paz, K., Lopez-Casas, P. P., Jones, S., Katz, A. M., Kann, L. M., López‐Ríos, F., Sarno, F., Al‐Shahrour, F., Vasquez, D., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3047 · Cited by 148
Bap1 is essential for kidney function and cooperates with Vhl in renal tumorigenesis
Wang, S., Gu, Y., Wolff, N. C., Stefanius, K., Christie, A. L., Dey, A., Hammer, R. E., Xie, X.-J., Rakheja, D., Pedrosa, I., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1414789111 · Cited by 152
The reverse evolution from multicellularity to unicellularity during carcinogenesis
Chen, H., Lin, F., Xing, K., & He, X. (2015) · Nature Communications · doi:10.1038/ncomms7367 · Cited by 155
Loi, S., Michiels, S., Lambrechts, D., Fumagalli, D., Claes, B., Kellokumpu‐Lehtinen, P., Bono, P., Kataja, V. V., Piccart, M. J., Joensuu, H., et al. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt121 · Cited by 147
Bundschuh, R. A., Dinges, J., Neumann, L., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.127340 · Cited by 147
Zhai, W., Lim, T. K. H., Zhang, T., Phang, S.-T., Tiang, Z., Guan, P., Ng, M.-H., Lim, J. Q., Yao, F., Li, Z., et al. (2017) · Nature Communications · doi:10.1038/ncomms14565 · Cited by 145
Li, W., Wang, H., Zhao, Z., Gao, H., Liu, C., Zhu, L., Wang, C., & Yang, Y. (2018) · Advanced Materials · doi:10.1002/adma.201805344 · Cited by 152
Lessons to learn from tumor-educated platelets
Roweth, H. G., & Battinelli, E. M. (2021) · Blood · doi:10.1182/blood.2019003976 · Cited by 147
Targeting PI3 kinase in cancer
Bauer, T. M., Patel, M. R., & Infante, J. R. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.09.006 · Cited by 153
Metadata
- Authors
- Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., Varela, I., Phillimore, B., Begum, S., McDonald, N. Q., Butler, A., Jones, D., Raine, K., Latimer, C., Santos, C. R., Nohadani, M., Eklund, A. C., Spencer-Dene, B., Clark, G., Pickering, L., Stamp, G., Gore, M., Szallasi, Z., Downward, J., Futreal, P. A., & Swanton, C.
- Affiliations
- Queen Mary University of London (GB)
- ORCID
- Gerlinger, Marco
- Rowan, Andrew J.
- Horswell, Stuart
- Larkin, James
- Endesfelder, David
- Gronroos, Eva
- Martinez, Pierre
- Tarpey, Patrick
- Varela, Ignacio
- Begum, Sharmin
- McDonald, Neil Q.
- Jones, David
- Raine, Keiran
- Latimer, Calli
- Eklund, Aron C.
- Pickering, Lisa
- Stamp, Gordon
- Downward, Julian
- Futreal, P. Andrew
- Swanton, Charles
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-03-08
- Volume
- 366
- Issue
- 10
- Pages
- 883-892
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4878653
- OpenAlex
- W2150575159
- Semantic Scholar
- b97108a8e1dd8cf67ff9f374a8237fabf4c96ad4
- Cited by
- 7,774
- References
- 35
- Citations by year
- 2026: 304 · 2025: 297 · 2024: 306 · 2023: 349 · 2022: 499 · 2021: 571 · 2020: 550 · 2019: 540 · 2018: 632 · 2017: 671 · 2016: 722 · 2015: 691 · 2014: 679 · 2013: 621 · 2012: 326
- FWCI
- 246.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Technical University of Denmark, DTU Orbit (Technical University of Denmark, DTU) (submittedVersion)
- Funders
- Wellcome Trust (079643)
- Cancer Research UK (10747, 15680)
- National Institute for Health and Care Research
- Medical Research Council
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- intratumoral heterogeneity, tumor evolution, renal carcinoma, metastatic renal cell carcinoma, phylogenetic inference, mTOR, SETD2, PTEN, KDM5C, tumor suppressor mutations, allelic imbalance, aneuploidy, gene expression signatures, biomarker development, personalized medicine
- MeSH terms
- Everolimus, Biopsy, Carcinoma, Renal Cell, Chromosome Aberrations, Humans, Immunosuppressive Agents, Kidney, Kidney Neoplasms, Mutation, Neoplasm Metastasis, Phenotype, Phylogeny, Ploidies, Biomarkers, Tumor, Sequence Analysis, DNA, Genetic Heterogeneity, Evolution, Molecular, Sirolimus, Polymorphism, Single Nucleotide, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
